Main Page
Faculty Deanship
Dean
Health Empowerment Unit
Strategic Planning Unit
Development and Quality Unit
Medical and Bioethics Unit
Vice Dean for Graduate Studies and Research
Vice Dean for Female Section
Vice dean for Academic Affairs
Examination and Assessment Unit
Internship and Alumni Unit
Student Research Unit
E-learning Unit
Student Mentoring and Support Unit
Community Service Unit
Talent and Creativity Care Unit
Continuing Education Unit
Neuroscience Research Unit
Vice Deanship of Clinical Affairs / Administration
Organizational Structure
Departments
Basic Sciences
Department of Anatomy
Department of Pharmacology
Department of Pathology
Department of Microbiology and Medical Parasitolog
Deparment of Clinical Biochemistry
Department of Physiology
Department of Medical Genetics
Clinical Sciences
Department of Otorhinolaryngology
Department of Obstetrics and Gynecology
Department of Hematology
Department of Medical Education
Department of Anesthesia
Department of Family Medicine
Department of Community Medicine
Department of Surgery
Department of Orthopedic Surgery
Department of ophthalmology
Department of Radiology
Department of Internal Medicine
Department of Pediatrics
Department of Emergency Medicine
Department of Urology
Department of Dermatology
Latest News
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Faculty of Medicine
Document Details
Document Type
:
Article In Journal
Document Title
:
Chlorambucil therapy in children with steroid-resistant nephrotic syndrome.
إستخدام عقار الكلوراميوسيل في علاج الأطفال الذين يعانون من متلازمة كلوية المقاومة الستيرويد
Document Language
:
English
Abstract
:
Chlorambucil (CHL) had been used as treatment for childhood nephrotic syndrome (NS) for more than half a century.1 It was used mainly in children with steroid sensitive nephrotic syndrome (SSNS) as steroid sparing agent in those with frequent relapsing or steroid dependent course. However, it was observed to result in higher rates of severe side effects and recommended as a second line drug after cyclophosphamide (CYC), which is considered as safer alkylating agent. The alkylating agents have been used for treating steroid resistant nephrotic syndrome (SRNS). In this retrospective study, we report our results of using CHL in children with SRNS secondary to IgM nephropathy, FSGS or diffuse mesangial hypercellularity (DMH). All patients presented to our unit over 20 months period (from February 2002 until June 2004) and were diagnosed as SRNS were recruited. We conclude that CHL therapy in a total accumulative dose of 15 mg/kg and 12 weeks duration could achieve complete remission in children with SRNS secondary to IgM nephropathy. Further randomized controlled studies are required
ISSN
:
8832-1012
Journal Name
:
Saudi Med J.
Volume
:
4
Issue Number
:
27
Publishing Year
:
2006 AH
2006 AD
Article Type
:
Article
Added Date
:
Wednesday, March 10, 2010
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
جميلة قاري
Kari, Jameela
Researcher
Doctorate
Files
File Name
Type
Description
25861.doc
doc
Back To Researches Page